Table 5.
Summary of survival results stratified by biomarker status.
| Markers | n | 3-year LRC | 3-year DFS | 3-year OS |
|---|---|---|---|---|
| All Patients | 106 | 89.7% | 74.0% | 77.7% |
|
| ||||
| p16+ | 70 | 96.6% | 88.9% | 92.8% |
| p16− | 36 | 75.4% | 46.3% | 49.8% |
| P value§ | 0.001 | <0.001 | <0.001 | |
|
| ||||
| EGFR+ | 27 | 85.0% | 72.3% | 82.3% |
| EGFR− | 74 | 90.7% | 74.5% | 76.6% |
| P value§ | 0.062 | 0.128 | 0.981 | |
|
| ||||
| HIF-1α (nuclear)+ | 26 | 84.3% | 67.6% | 76.6% |
| HIF-1α (nuclear)− | 32 | 100% | 85.1% | 90.1% |
| P value§ | 0.019 | 0.093 | 0.328 | |
|
| ||||
| Cyclin D1+ | 41 | 89.2% | 67.8% | 78.2% |
| Cyclin D1− | 18 | 100% | 94.1% | 92.9% |
| P value§ | 0.117 | 0.019 | 0.094 | |
§Log-rank test.